Market Overview:
The global spinal muscular atrophy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of spinal muscular atrophy, rising awareness about available treatments, and growing investment in research and development for new therapies. The global spinal muscular atrophy market is segmented on the basis of type into early stage candidates and late stage candidates. The early stage candidates segment is expected to account for the majority share of the global market in 2018 owing to the large number of drugs in development for this indication. However, the late stage candidates segment is projected to grow at a higher CAGR during the forecast period as a result of increasing approvals for novel therapies.
Product Definition:
Spinal Muscular Atrophy is a neuromuscular disorder that affects the control of muscle movement. It is caused by the loss of motor neurons in the spinal cord and brainstem, which leads to a decrease in muscle mass and strength. This can affect activities such as walking, crawling, or even breathing. SMA is considered to be one of the leading causes of death in infants and young children.
Early Stage Candidates:
Early-stage candidates are molecules that have the potential to address a significant unmet medical need. They can be used in various therapeutic areas including central nervous system disorders, oncology, cardiology and others. Spinal Muscular Atrophy (SMA) is one of the most common fatal genetic motor neuron diseases occurring in infants and young children with progressive respiratory failure leading to death within 3-5 years of diagnosis.
Late Stage Candidates:
Late-stage candidates are the drugs that have completed Phase II clinical trials and possess an excellent safety profile. These drugs can be used to treat SMA gene mutation carriers. Currently, there are two late-stage candidates in the market for spinal muscular atrophy: Nuedexta and Vyndaqel.
Application Insights:
The hospital application segment dominated the global spinal muscular atrophy market in 2017. This can be attributed to a large patient base and high prevalence of SMA. According to the data published by the U.S. National Library of Medicine, around 1 in every 3,600 babies is born with SMA worldwide while about 1 in every 2,000 infants are diagnosed with this condition within birth span across Europe and North America regions respectively.
Clinic applications for screening.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to high awareness levels and availability of effective treatment methods for SMA patients. Asia Pacific, on the other hand, is anticipated to exhibit lucrative growth over the forecast period owing to rising healthcare spending by governments as well as private organizations and increasing awareness about available treatments for SMA patients. Moreover, an increase in birth rate has resulted in a rise in number of candidates diagnosed with spinal muscular atrophy; hence creating demand for research focused on early diagnosis of this disease so that proper treatment can be provided at an early stage thereby benefitting patient care experience.
Growth Factors:
- Increasing incidence of SMA due to rising awareness about the disease
- Growing demand for effective and affordable treatment options for SMA
- Rising number of clinical trials for new drugs and therapies for SMA
- increasing investment by pharmaceutical companies in research and development of new treatments for SMA
- Growing number of patients diagnosed with SMA
Scope Of The Report
Report Attributes
Report Details
Report Title
Spinal Muscular Atrophy Market Research Report
By Type
Early Stage Candidates, Late Stage Candidates
By Application
Hospital, Clinic, Others
By Companies
Lonis Pharmaceuticals, F. Hoffmann-La Roche, AveXis, Novartis, Cytokinetics, Ionis Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
164
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Spinal Muscular Atrophy Market Report Segments:
The global Spinal Muscular Atrophy market is segmented on the basis of:
Types
Early Stage Candidates, Late Stage Candidates
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lonis Pharmaceuticals
- F. Hoffmann-La Roche
- AveXis
- Novartis
- Cytokinetics
- Ionis Pharmaceuticals
Highlights of The Spinal Muscular Atrophy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Early Stage Candidates
- Late Stage Candidates
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Spinal Muscular Atrophy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Spinal muscular atrophy (SMA) is a rare genetic disorder that causes muscle weakness and wasting in the lower body. The muscles become less able to contract, causing them to weaken and waste away. This can lead to difficulty walking, climbing stairs, and moving around on your own. SMA is most common in boys but can also occur in girls.
Some of the key players operating in the spinal muscular atrophy market are Lonis Pharmaceuticals, F. Hoffmann-La Roche, AveXis, Novartis, Cytokinetics, Ionis Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Spinal Muscular Atrophy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Spinal Muscular Atrophy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Spinal Muscular Atrophy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Spinal Muscular Atrophy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Spinal Muscular Atrophy Market Size & Forecast, 2020-2028
4.5.1 Spinal Muscular Atrophy Market Size and Y-o-Y Growth
4.5.2 Spinal Muscular Atrophy Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Early Stage Candidates
5.2.2 Late Stage Candidates
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Spinal Muscular Atrophy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Spinal Muscular Atrophy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Early Stage Candidates
9.6.2 Late Stage Candidates
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Early Stage Candidates
10.6.2 Late Stage Candidates
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Early Stage Candidates
11.6.2 Late Stage Candidates
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Early Stage Candidates
12.6.2 Late Stage Candidates
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Early Stage Candidates
13.6.2 Late Stage Candidates
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Spinal Muscular Atrophy Market: Competitive Dashboard
14.2 Global Spinal Muscular Atrophy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Lonis Pharmaceuticals
14.3.2 F. Hoffmann-La Roche
14.3.3 AveXis
14.3.4 Novartis
14.3.5 Cytokinetics
14.3.6 Ionis Pharmaceuticals
